一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 検索用
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 全文PDF

Abstract

Full Text of PDF Full Text of PDF (580k)
Article in Japanese

Case Report

A case of low-dose everolimus (Certican®)-induced pneumonitis

Noriko Takedaa  Kazuhisa Asaia  Naoki Ijiria  Hiroshi Kanazawaa  Junji Uchidab  Kazuto Hirataa 

aDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka City University
bDepartment of Urology, Graduate School of Medicine, Osaka City University

ABSTRACT

A 70-year-old Japanese man underwent living-donor renal transplantation, with his wife being the donor, in June 2011 for end-stage renal dysfunction. He started receiving low-dose everolimus for immunosuppression from September 2012. Three months later he gradually developed dyspnea (mMRC [modified Medical Research Council] Breathlessness Scale grade 2). His chest computed tomography (CT) scan showed ground-glass opacity. At first, opportunistic infections were suspected and empirical therapies were started. However, the bronchoalveolar lavage fluid (BALF) demonstrated negative results for infection. The percentage of lymphocytes in BALF had significantly increased (54%), and a transbronchial lung biospy (TBLB) specimen showed organizing pneumonia. Drug-induced pneumonitis was suspected, and low-dose everolimus was stopped. After which the patient's symptoms and CT findings improved. We eventually diagnosed a case of low-dose everolimus-induced pneumonitis. Although everolimus-induced pneumonitis is frequently observed in cases of advanced renal cell carcinoma, low-dose everolimus-induced pneumonitis is rare and has never been reported in Japan. To the best of our knowledge, this is the first case of low-dose everolimus-induced pneumonitis in this country.

KEYWORDS

Drug-induced pneumonitis  Everolimus (Certican®)  Renal transplantation  Immunosuppressant 

Received 22 Apr 2013 / Accepted 11 Oct 2013

AJRS, 3(2): 227-231, 2014

Google Scholar